Trial characteristics
	Further details
Single centre/multicenter
Country/Countries
How was participant eligibility defined?
How many people were randomized?
Number of participants in each intervention group
Number of participants who received intended treatment
Number of participants who were analysed
Drug treatment(s) used
Dose/frequency of administration
Duration of treatment (state weeks/months, etc, if cross‐over trial give length of time in each arm)
Median (range) length of follow up reported in this paper (state weeks, months or years or if not
Time‐points when measurements were taken during the study
Time‐points reported in the study
Time‐points you are using in RevMan 5.0
Trial design (e.g. parallel/cross‐over*)
Other